Document text
Principal Investigator: Yajing Wang
Organization: UNIVERSITY OF ALABAMA AT BIRMINGHAM
Fiscal Year: 2024
Award: $359,006
Funding agency: National Heart Lung and Blood Institute
With continually improving reperfusion strategies, the overall mortality of AMI has been significantly reduced in
non-diabetic patients. However, both the prevalence and severity of ischemic heart failure (IHF) continually
escalate in patients with type 2 diabetes. Identifying risk factors, pathological mechanisms, and effective
interventions blocking diabetic exacerbation of IHF are urgently needed. Endothelial injury and resultant coronary
microvascular dysfunction (CMD) are the hallmarks of diabetic cardiovascular complications, hindering adequate
reperfusion despite successful recanalization. Clarifying mechanisms responsible for diabetic CMD and
identifying effective interventions improving coronary circulation are essential in reducing diabetic IHF
exacerbation. Research in the past decade has increased understanding of the roles adipocytes (ADp) play in
health and disease. Functional ADp are critical in maintaining systemic metabolic hemostasis, whereas ADp
dysfunction is one of the most recognized pathogenic factors leading to type 2 diabetes. A complete
understanding of the molecular mechanisms mediating the communication between adipose tissue and heart
will undoubtedly help the development of effective therapies against diabetic cardiovascular death. Extracellular
vesicles, particularly exosomes (Exo), are increasingly recognized as systemic messengers mediating inter-
cellular/inter-organ communication. Evidence from our recently published work and additional preliminary data
strongly suggest that GRK5-induced coronary microcirculatory endothelial cells (CMEC) adiponectin receptor 1
(AdipoR1) phosphorylation is responsible for attenuated ADp-derived Exo (ADp-Exo) protective signaling and
increased cytotoxic ADp-Exo uptake in diabetic CMEC, contributing to diabetic exacerbation of CMD and IHF.
Targeting the GRK5-AdipoR1 system may be a novel therapeutic intervention against diabetic CMD, ultimately
protecting the heart against IHF. This novel hypothesis will be rigorously investigated in 3 specific aims. Utilizing
genetic gain- and loss-of-function approaches, Specific Aim 1 will test a hypothesis that diabetes-induced CMEC
AdipoR1 phosphorylation blocks ADp-Exo mediated vasculoprotection, contributing to diabetic CMD and IHF
exacerbation. Specific Aim 2 will test a novel hypothesis that diabetic AdipoR1 phosphorylation and resultant
endocytosis promotes CMEC uptake of cytotoxic ADp-Exo via adiponectin (on ADp-Exo surface) interaction with
AdipoR1 (expressed in CMEC). Specific Aim 3 will determine whether 1) EC AdipoR1 phosphorylation mediates
diabetic ADp-Exo induced CMD and IHF, and 2) blocking EC AdipoR1 phosphorylation is effective in protecting
diabetes-exacerbated CMD and IHF. Successful completion of these studies will reveal a novel molecular
mechanism responsible for the diabetic exacerbation of cardiovascular injury, and potentially identify novel
therapy against CMD and post-MI remodeling in diabetic patients. Moreover, successful completion of the
proposed studies may have broader implications in the development of other diseases involving Exo, as our
work will help to fill a knowledge gap concerning cell/tissue-selective recognition of circulating Exo.
Terms: <ACRP30 protein><Acceleration><Acute><Acute myocardial infarct><Acute myocardial infarction><Adipocytes><Adipose Cell><Adipose tissue><Adult-Onset Diabetes Mellitus><Affect><Attenuated><Body Tissues><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cell Body><Cell Communication><Cell Communication and Signaling><Cell Interaction><Cell Signaling><Cell-to-Cell Interaction><Cells><Cessation of life><Communication><Coronary><Coronary Circulation><Data><Death><Development><Diabetes Mellitus><Disease><Disorder><Dysfunction><Endocytosis><Endothelial Cells><Endothelium><Fat Cells><Fatty Tissue><Functional disorder><G Protein-Coupled Receptor Kinase 5><GPRK5><GPRK5 Gene><GRK5><GRK5 gene><Genetic><Health><Heart><Heart Vascular><Heart failure><Hemostasis><Hemostatic function><Human><Injury><Intracellular Communication and Signaling><Ischemic Heart><Ischemic Heart Disease><Ischemic myocardium><Ketosis-Resistant Diabetes Mellitus><Kinases><Knowledge><Label><Lipocytes><Mature Lipocyte><Mature fat cell><Maturity-Onset Diabetes Mellitus><Mediating><Metabolic><Microvascular Dysfunction><Modern Man><Molecular><Morbidity><Morbidity - disease rate><Myocardial Ischemia><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Organ><Pathogenicity Factors><Pathologic><Patient Care><Patient Care Delivery><Patients><Persons><Phenotype><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Physiopathology><Play><Population><Prevalence><Production><Protein Phosphorylation><Publishing><Receptor Protein><Regulation><Reperfusion Therapy><Reporting><Research><Risk Factors><Role><Severities><Signal Transduction><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Surface><System><T2 DM><T2D><T2DM><Testing><Tissues><Transphosphorylases><Type 2 Diabetes Mellitus><Type 2 diabetes><Type 2 diabetic><Type II Diabetes Mellitus><Type II diabetes><Type II diabetic><Vascular Endothelial Cell><Virulence Factors><Work><adipocyte complement-related protein 30-kDa><adipocyte, C1q and collagen domain containing protein><adipocytokines><adipokines><adiponectin><adipose><adult onset diabetes><apM-1 protein><apM1 (adipose-specific) protein><attenuate><attenuates><biological signal transduction><cardiac failure><cardiac ischemia><cardioprotectant><cardioprotection><cardioprotective><cardiovascular injury><care for patients><care of patients><caring for patients><circulatory system><coronary ischemia><cytotoxic><developmental><diabetes><diabetic><diabetic patient><effective intervention><effective therapy><effective treatment><exosome><experiment><experimental research><experimental study><experiments><extracellular vesicles><gain of function><heart ischemia><improved><in vivo><injuries><intravenous administration><ketosis resistant diabetes><loss of function><maturity onset diabetes><microvascular complications><microvascular disease><mortality><myocardial ischemia/hypoxia><myocardium ischemia><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><non-diabetic><nondiabetic><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><overexpress><overexpression><pathophysiology><prevent><preventing><receptor><reperfusion><small vessel disease><social role><type 2 DM><type II DM><type two diabetes><uptake><white adipose tissue><yellow adipose tissue>